189 results
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
7 Mar 24
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
4:10pm
) in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and marginal zone
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
9 Nov 23
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
4:15pm
), chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL), which resulted in 100% progression free survival (PFS) at 42 months in CLL
8-K
EX-99.1
kerj9k53ked8550zrb0d
10 Aug 23
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results
4:11pm
8-K
EX-99.1
e6okzq4d hbb1j880iwc
4 May 23
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results
4:10pm
8-K
szr6iqk sn
3 Apr 23
Results of Operations and Financial Condition
4:20pm
8-K
8r4oy7y5m76 vm3
12 Dec 22
Other Events
6:03am
8-K
EX-99.1
gv4r72u
3 Nov 22
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results
4:17pm
8-K
knja68gir51ut4 dqvx
26 May 22
Other Events
5:25pm
8-K
EX-99.1
5fgff
5 May 22
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2022 Financial Results
12:00am
8-K
EX-99.1
d1rvqri wc8z0
10 Mar 22
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2021 Financial Results
4:15pm
424B5
qr54z q85bdhtt
17 Dec 21
Prospectus supplement for primary offering
5:15pm
8-K
3hew4tvsrsr15w5z3zr
13 Dec 21
Other Events
4:00pm